{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:41:50Z","timestamp":1790667710734,"version":"4.1.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40263-024-01068-1","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T11:02:56Z","timestamp":1708599776000},"page":"193-204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Unmet Needs in Psychodermatology: A Narrative Review"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-5211","authenticated-orcid":false,"given":"Rachel E.","family":"Christensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6358-9068","authenticated-orcid":false,"given":"Mohammad","family":"Jafferany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"1068_CR1","doi-asserted-by":"crossref","unstructured":"Ferreira BR, Vulink N, Mostaghimi L, et al. Classification of psychodermatological disorders: proposal of a new international classification. J Eur Acad Dermatol Venereol. 2023 (epub 2023\/12\/12).","DOI":"10.1111\/jdv.19731"},{"issue":"5","key":"1068_CR2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1046\/j.1365-2133.2000.03831.x","volume":"143","author":"A Picardi","year":"2000","unstructured":"Picardi A, Abeni D, Melchi CF, et al. Psychiatric morbidity in dermatological outpatients: an issue to be recognized. Br J Dermatol. 2000;143(5):983\u201391.","journal-title":"Br J Dermatol"},{"key":"1068_CR3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1192\/bjp.143.1.51","volume":"143","author":"JE Hughes","year":"1983","unstructured":"Hughes JE, Barraclough BM, Hamblin LG, et al. Psychiatric symptoms in dermatology patients. Br J Psychiatry. 1983;143:51\u20134.","journal-title":"Br J Psychiatry"},{"issue":"8","key":"1068_CR4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017173","volume":"7","author":"J Wang","year":"2017","unstructured":"Wang J, Wu X, Lai W, et al. Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis. BMJ Open. 2017;7(8): e017173.","journal-title":"BMJ Open"},{"issue":"6","key":"1068_CR5","doi-asserted-by":"crossref","DOI":"10.1002\/ski2.294","volume":"3","author":"F Balieva","year":"2023","unstructured":"Balieva F, Abebe DS, Dalgard FJ, et al. Risk of developing psychiatric disease among adult patients with skin disease: a 9-year national register follow-up study in Norway. Skin Health Dis. 2023;3(6): e294.","journal-title":"Skin Health Dis."},{"issue":"1","key":"1068_CR6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0190-9622(87)70176-5","volume":"17","author":"L Gaston","year":"1987","unstructured":"Gaston L, Lassonde M, Bernier-Buzzanga J, et al. Psoriasis and stress: a prospective study. J Am Acad Dermatol. 1987;17(1):82\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1068_CR7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/jamadermatol.2021.1450","volume":"157","author":"E Hedman-Lagerl\u00f6f","year":"2021","unstructured":"Hedman-Lagerl\u00f6f E, Fust J, Axelsson E, et al. Internet-delivered cognitive behavior therapy for atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(7):796\u2013804.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1068_CR8","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1111\/ajd.12640","volume":"59","author":"TJ Stewart","year":"2018","unstructured":"Stewart TJ, Schut C, Whitfeld M, et al. Cross-sectional study of psychological stress and skin symptoms in Australian university students. Australas J Dermatol. 2018;59(1):e82\u20134.","journal-title":"Australas J Dermatol"},{"issue":"1","key":"1068_CR9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.15537\/smj.2018.1.21231","volume":"39","author":"GA Bin Saif","year":"2018","unstructured":"Bin Saif GA, Alotaibi HM, Alzolibani AA, et al. Association of psychological stress with skin symptoms among medical students. Saudi Med J. 2018;39(1):59\u201366.","journal-title":"Saudi Med J"},{"key":"1068_CR10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1146\/annurev-psych-020122-041854","volume":"74","author":"AS Troy","year":"2023","unstructured":"Troy AS, Willroth EC, Shallcross AJ, et al. Psychological resilience: an affect-regulation framework. Annu Rev Psychol. 2023;74:547\u201376.","journal-title":"Annu Rev Psychol"},{"issue":"4","key":"1068_CR11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2340\/00015555-1557","volume":"93","author":"JE Kim","year":"2013","unstructured":"Kim JE, Cho BK, Cho DH, et al. Expression of hypothalamic-pituitary-adrenal axis in common skin diseases: evidence of its association with stress-related disease activity. Acta Derm Venereol. 2013;93(4):387\u201393.","journal-title":"Acta Derm Venereol"},{"key":"1068_CR12","volume":"2012","author":"JM Hall","year":"2012","unstructured":"Hall JM, Cruser D, Podawiltz A, et al. Psychological stress and the cutaneous immune response: roles of the HPA axis and the sympathetic nervous system in atopic dermatitis and psoriasis. Dermatol Res Pract. 2012;2012: 403908.","journal-title":"Dermatol Res Pract"},{"issue":"6","key":"1068_CR13","doi-asserted-by":"crossref","first-page":"C1757","DOI":"10.1152\/ajpcell.00147.2022","volume":"323","author":"AT Slominski","year":"2022","unstructured":"Slominski AT, Slominski RM, Raman C, et al. Neuroendocrine signaling in the skin with a special focus on the epidermal neuropeptides. Am J Physiol Cell Physiol. 2022;323(6):C1757\u201376.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"7","key":"1068_CR14","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00403-023-02542-4","volume":"315","author":"JJ Keller","year":"2023","unstructured":"Keller JJ. Cutaneous neuropeptides: the missing link between psychological stress and chronic inflammatory skin disease? Arch Dermatol Res. 2023;315(7):1875\u201381.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"1068_CR15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217-28.e13.","journal-title":"Cell"},{"issue":"3","key":"1068_CR16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.0022-202X.2003.12602.x","volume":"122","author":"SP Raychaudhuri","year":"2004","unstructured":"Raychaudhuri SP, Sanyal M, Weltman H, et al. K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model. J Invest Dermatol. 2004;122(3):812\u20139.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1068_CR17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/jid.2010.317","volume":"131","author":"EM Peters","year":"2011","unstructured":"Peters EM, Liezmann C, Spatz K, et al. Nerve growth factor partially recovers inflamed skin from stress-induced worsening in allergic inflammation. J Invest Dermatol. 2011;131(3):735\u201343.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1068_CR18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.clinthera.2020.03.008","volume":"42","author":"N Pondeljak","year":"2020","unstructured":"Pondeljak N, Lugovi\u0107-Mihi\u0107 L. Stress-induced interaction of skin immune cells, hormones, and neurotransmitters. Clin Ther. 2020;42(5):757\u201370.","journal-title":"Clin Ther"},{"issue":"3","key":"1068_CR19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4088\/PCC.v09n0306","volume":"9","author":"M Jafferany","year":"2007","unstructured":"Jafferany M. Psychodermatology: a guide to understanding common psychocutaneous disorders. Prim Care Companion J Clin Psychiatry. 2007;9(3):203\u201313.","journal-title":"Prim Care Companion J Clin Psychiatry."},{"issue":"2","key":"1068_CR20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jaad.2020.02.040","volume":"83","author":"DV Samuels","year":"2020","unstructured":"Samuels DV, Rosenthal R, Lin R, et al. Acne vulgaris and risk of depression and anxiety: a meta-analytic review. J Am Acad Dermatol. 2020;83(2):532\u201341.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1068_CR21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.anai.2019.06.002","volume":"123","author":"BT Cheng","year":"2019","unstructured":"Cheng BT, Silverberg JI. Depression and psychological distress in US adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):179\u201385.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1068_CR22","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.1386","volume":"102","author":"I Jalenques","year":"2022","unstructured":"Jalenques I, Bourlot F, Martinez E, et al. Prevalence and odds of anxiety disorders and anxiety symptoms in children and adults with psoriasis: Systematic review and meta-analysis. Acta Derm Venereol. 2022;102: adv00769.","journal-title":"Acta Derm Venereol."},{"issue":"6","key":"1068_CR23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021;22(6):757\u201374.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1068_CR24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1159\/000453355","volume":"232","author":"A Kouris","year":"2016","unstructured":"Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology. 2016;232(6):687\u201391.","journal-title":"Dermatology"},{"issue":"2","key":"1068_CR25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamadermatol.2017.5540","volume":"154","author":"K McDonald","year":"2018","unstructured":"McDonald K, Shelley A, Jafferany M. The PHQ-2 in dermatology-standardized screening for depression and suicidal ideation. JAMA Dermatol. 2018;154(2):139\u201341.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"1068_CR26","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/jocd.15685","volume":"22","author":"IN Pereira","year":"2023","unstructured":"Pereira IN, Chattopadhyay R, Fitzpatrick S, et al. Evidence-based review: screening body dysmorphic disorder in aesthetic clinical settings. J Cosmet Dermatol. 2023;22(7):1951\u201366.","journal-title":"J Cosmet Dermatol"},{"issue":"46","key":"1068_CR27","volume":"100","author":"C Tan","year":"2021","unstructured":"Tan C, Jiang J, Deng X, et al. Effect of cognitive behavioral therapy on anxiety and depression in patients with psoriasis: a protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021;100(46): e27720.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1068_CR28","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1080\/09546634.2020.1776207","volume":"33","author":"V Mashayekhi Goyonlo","year":"2022","unstructured":"Mashayekhi Goyonlo V, Sardabi MS, Tavalaei AM, et al. Cognitive behavioral therapy as an adjuvant therapy in acne excori\u00e9e: a randomized controlled clinical trial. J Dermatolog Treat. 2022;33(2):782\u20138.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1068_CR29","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13811","volume":"33","author":"J Skurya","year":"2020","unstructured":"Skurya J, Jafferany M, Everett GJ. Habit reversal therapy in the management of body focused repetitive behavior disorders. Dermatol Ther. 2020;33(6): e13811.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1068_CR30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/bjd.16009","volume":"178","author":"P Nor\u00e9n","year":"2018","unstructured":"Nor\u00e9n P, Hagstr\u00f6mer L, Alimohammadi M, et al. The positive effects of habit reversal treatment of scratching in children with atopic dermatitis: a randomized controlled study. Br J Dermatol. 2018;178(3):665\u201373.","journal-title":"Br J Dermatol"},{"issue":"217","key":"1068_CR31","first-page":"91","volume":"96","author":"S Piaserico","year":"2016","unstructured":"Piaserico S, Marinello E, Dessi A, et al. Efficacy of biofeedback and cognitive-behavioural therapy in psoriatic patients: a single-blind, randomized and controlled study with added narrow-band ultraviolet B therapy. Acta Derm Venereol. 2016;96(217):91\u20135.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1068_CR32","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14030","volume":"33","author":"RJ Neerackal","year":"2020","unstructured":"Neerackal RJ, Abdul Latheef EN, Sukumarakurup S, et al. Relaxation therapy in the management of psoriasis. Dermatol Ther. 2020;33(6): e14030.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1068_CR33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaad.2016.10.012","volume":"76","author":"R Gallo","year":"2017","unstructured":"Gallo R, Chiorri C, Gasparini G, et al. Can mindfulness-based interventions improve the quality of life of patients with moderate\/severe alopecia areata? A prospective pilot study. J Am Acad Dermatol. 2017;76(4):757\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1068_CR34","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2009.06.029","volume":"62","author":"R Willemsen","year":"2010","unstructured":"Willemsen R, Haentjens P, Roseeuw D, et al. Hypnosis in refractory alopecia areata significantly improves depression, anxiety, and life quality but not hair regrowth. J Am Acad Dermatol. 2010;62(3):517\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1068_CR35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archpsyc.59.4.381","volume":"59","author":"KA Phillips","year":"2002","unstructured":"Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002;59(4):381\u20138.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"1068_CR36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/01.yic.0000194378.65460.ef","volume":"21","author":"KA Phillips","year":"2006","unstructured":"Phillips KA. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol. 2006;21(3):177\u20139.","journal-title":"Int Clin Psychopharmacol"},{"issue":"9","key":"1068_CR37","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1176\/appi.ajp.2016.15091243","volume":"173","author":"KA Phillips","year":"2016","unstructured":"Phillips KA, Keshaviah A, Dougherty DD, et al. Pharmacotherapy relapse prevention in body dysmorphic disorder: a double-blind, placebo-controlled trial. Am J Psychiatry. 2016;173(9):887\u201395.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1068_CR38","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4088\/JCP.v64n0615","volume":"64","author":"KA Phillips","year":"2003","unstructured":"Phillips KA, Najjar F. An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry. 2003;64(6):715\u201320.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1068_CR39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4088\/JCP.v62n0203","volume":"62","author":"KA Phillips","year":"2001","unstructured":"Phillips KA, McElroy SL, Dwight MM, et al. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 2001;62(2):87\u201391.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1068_CR40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4088\/JCP.v59n0404","volume":"59","author":"KA Phillips","year":"1998","unstructured":"Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 1998;59(4):165\u201371.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1068_CR41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00004850-199612000-00006","volume":"11","author":"G Perugi","year":"1996","unstructured":"Perugi G, Giannotti D, Di Vaio S, et al. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol. 1996;11(4):247\u201354.","journal-title":"Int Clin Psychopharmacol"},{"issue":"11","key":"1068_CR42","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archpsyc.56.11.1033","volume":"56","author":"E Hollander","year":"1999","unstructured":"Hollander E, Allen A, Kwon J, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999;56(11):1033\u20139.","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"1068_CR43","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/PRA.0000000000000415","volume":"25","author":"A Fang","year":"2019","unstructured":"Fang A, Porth R, Phillips KA, et al. Personality as a predictor of treatment response to escitalopram in adults with body dysmorphic disorder. J Psychiatr Pract. 2019;25(5):347\u201357.","journal-title":"J Psychiatr Pract"},{"issue":"1","key":"1068_CR44","first-page":"175","volume":"32","author":"KA Phillips","year":"1996","unstructured":"Phillips KA. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Psychopharmacol Bull. 1996;32(1):175\u201380.","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"1068_CR45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1176\/appi.ajp.162.2.377","volume":"162","author":"KA Phillips","year":"2005","unstructured":"Phillips KA. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. 2005;162(2):377\u20139.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"1068_CR46","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1176\/appi.ajp.162.5.1022-a","volume":"162","author":"KA Phillips","year":"2005","unstructured":"Phillips KA. Olanzapine augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. 2005;162(5):1022\u20133.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1068_CR47","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1017\/S1092852900016291","volume":"13","author":"A Allen","year":"2008","unstructured":"Allen A, Hadley SJ, Kaplan A, et al. An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectr. 2008;13(2):138\u201344.","journal-title":"CNS Spectr"},{"issue":"5","key":"1068_CR48","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1017\/S1092852900025414","volume":"14","author":"KA Phillips","year":"2009","unstructured":"Phillips KA, Menard W. A prospective pilot study of levetiracetam for body dysmorphic disorder. CNS Spectr. 2009;14(5):252\u201360.","journal-title":"CNS Spectr"},{"key":"1068_CR49","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jpsychires.2023.03.031","volume":"161","author":"FR Schneier","year":"2023","unstructured":"Schneier FR, Feusner J, Wheaton MG, et al. Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. J Psychiatr Res. 2023;161:364\u201370.","journal-title":"J Psychiatr Res"},{"issue":"5","key":"1068_CR50","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.jaad.2018.12.012","volume":"80","author":"EH Campbell","year":"2019","unstructured":"Campbell EH, Elston DM, Hawthorne JD, et al. Diagnosis and management of delusional parasitosis. J Am Acad Dermatol. 2019;80(5):1428\u201334.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1068_CR51","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/ijd.13004","volume":"55","author":"AC Martins","year":"2016","unstructured":"Martins AC, Mendes CP, Nico MM. Delusional infestation: a case series from a university dermatology center in S\u00e3o Paulo, Brazil. Int J Dermatol. 2016;55(8):864\u20138.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1068_CR52","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2340\/00015555625558","volume":"62","author":"K Hamann","year":"1982","unstructured":"Hamann K, Avnstorp C. Delusions of infestation treated by pimozide: a double-blind crossover clinical study. Acta Derm Venereol. 1982;62(1):55\u20138.","journal-title":"Acta Derm Venereol"},{"key":"1068_CR53","doi-asserted-by":"crossref","unstructured":"Laidler N. Delusions of parasitosis: a brief review of the literature and pathway for diagnosis and treatment. Dermatol Online J. 2018;24(1).","DOI":"10.5070\/D3241037923"},{"issue":"5","key":"1068_CR54","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JCP.0b013e318185e774","volume":"28","author":"RW Freudenmann","year":"2008","unstructured":"Freudenmann RW, Lepping P. Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy. J Clin Psychopharmacol. 2008;28(5):500\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1068_CR55","volume":"5","author":"JD Lu","year":"2022","unstructured":"Lu JD, Gotesman RD, Varghese S, et al. Treatments for primary delusional infestation: systematic review. JMIR Dermatol. 2022;5(1): e34323.","journal-title":"JMIR Dermatol."},{"issue":"4","key":"1068_CR56","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1365-2133.2011.10426.x","volume":"165","author":"S Wong","year":"2011","unstructured":"Wong S, Bewley A. Patients with delusional infestation (delusional parasitosis) often require prolonged treatment as recurrence of symptoms after cessation of treatment is common: an observational study. Br J Dermatol. 2011;165(4):893\u20136.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1068_CR57","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archpsyc.60.5.517","volume":"60","author":"A van Minnen","year":"2003","unstructured":"van Minnen A, Hoogduin KA, Keijsers GP, et al. Treatment of trichotillomania with behavioral therapy or fluoxetine: a randomized, waiting-list controlled study. Arch Gen Psychiatry. 2003;60(5):517\u201322.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"1068_CR58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4088\/JCP.v61n0111","volume":"61","author":"PT Ninan","year":"2000","unstructured":"Ninan PT, Rothbaum BO, Marsteller FA, et al. A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. J Clin Psychiatry. 2000;61(1):47\u201350.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1068_CR59","volume":"2008","author":"GM Soomro","year":"2008","unstructured":"Soomro GM, Altman D, Rajagopal S, et al. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;2008(1): CD001765.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1068_CR60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/JCP.0000000000000462","volume":"36","author":"MC Schumer","year":"2016","unstructured":"Schumer MC, Bartley CA, Bloch MH. Systematic review of pharmacological and behavioral treatments for skin picking disorder. J Clin Psychopharmacol. 2016;36(2):147\u201352.","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"1068_CR61","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.4088\/JCP.09m05114gre","volume":"71","author":"M Van Ameringen","year":"2010","unstructured":"Van Ameringen M, Mancini C, Patterson B, et al. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry. 2010;71(10):1336\u201343.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1068_CR62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4088\/JCP.v64n0110","volume":"64","author":"RS Stewart","year":"2003","unstructured":"Stewart RS, Nejtek VA. An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. J Clin Psychiatry. 2003;64(1):49\u201352.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1068_CR63","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/JCP.0b013e318221b1ba","volume":"31","author":"MP White","year":"2011","unstructured":"White MP, Koran LM. Open-label trial of aripiprazole in the treatment of trichotillomania. J Clin Psychopharmacol. 2011;31(4):503\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"1068_CR64","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/JCP.0b013e3181e617a1","volume":"30","author":"JE Grant","year":"2010","unstructured":"Grant JE, Odlaug BL, Chamberlain SR, et al. A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response. J Clin Psychopharmacol. 2010;30(4):396\u2013403.","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"1068_CR65","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.4088\/JCP.v68n0909","volume":"68","author":"JE Grant","year":"2007","unstructured":"Grant JE, Odlaug BL, Kim SW. Lamotrigine treatment of pathologic skin picking: an open-label study. J Clin Psychiatry. 2007;68(9):1384\u201391.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1068_CR66","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamapsychiatry.2016.0060","volume":"73","author":"JE Grant","year":"2016","unstructured":"Grant JE, Chamberlain SR, Redden SA, et al. N-acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial. JAMA Psychiat. 2016;73(5):490\u20136.","journal-title":"JAMA Psychiat"},{"issue":"5","key":"1068_CR67","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1176\/appi.ajp.20220737","volume":"180","author":"JE Grant","year":"2023","unstructured":"Grant JE, Chesivoir E, Valle S, et al. Double-blind placebo-controlled study of memantine in trichotillomania and skin-picking disorder. Am J Psychiatry. 2023;180(5):348\u201356.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1068_CR68","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaad.2012.04.007","volume":"68","author":"SN Gee","year":"2013","unstructured":"Gee SN, Zakhary L, Keuthen N, et al. A survey assessment of the recognition and treatment of psychocutaneous disorders in the outpatient dermatology setting: how prepared are we? J Am Acad Dermatol. 2013;68(1):47\u201352.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1068_CR69","doi-asserted-by":"crossref","first-page":"41972","DOI":"10.4088\/PCC.21r03175","volume":"24","author":"RE Christensen","year":"2022","unstructured":"Christensen RE, Jafferany M. Global awareness, knowledge, and practice patterns of psychocutaneous medicine: a primary care perspective. Prim Care Companion CNS Disord. 2022;24(4):41972.","journal-title":"Prim Care Companion CNS Disord."},{"issue":"8","key":"1068_CR70","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s00403-023-02631-4","volume":"315","author":"A Senulyt\u0117","year":"2023","unstructured":"Senulyt\u0117 A, Vasiliauskait\u0117 G, Rudzikait\u0117-Fergiz\u0117 G, et al. Psychodermatology in Lithuania. A survey on knowledge, awareness, and practice patterns in Lithuanian dermatovenereologists. Arch Dermatol Res. 2023;315(8):2351\u20137.","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"1068_CR71","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/ced\/llad204","volume":"48","author":"S Ait Oussous","year":"2023","unstructured":"Ait Oussous S, Jafferany M, Chakiri R. Psychodermatology knowledge, awareness and patterns of practice among Moroccan dermatologists: a national survey study. Clin Exp Dermatol. 2023;48(10):1152\u20134.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1068_CR72","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1468-3083.2006.01910.x","volume":"21","author":"F Poot","year":"2007","unstructured":"Poot F, Sampogna F, Onnis L. Basic knowledge in psychodermatology. J Eur Acad Dermatol Venereol. 2007;21(2):227\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1068_CR73","doi-asserted-by":"crossref","unstructured":"Ryan MP, Wagner RF. Psychodermatology fellowship: is it time? Dermatol Online J. 2021;27(2).","DOI":"10.5070\/D3272052383"},{"issue":"6","key":"1068_CR74","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamadermatol.2020.0394","volume":"156","author":"A Patel","year":"2020","unstructured":"Patel A, Jafferany M. Multidisciplinary and holistic models of care for patients with dermatologic disease and psychosocial comorbidity: a systematic review. JAMA Dermatol. 2020;156(6):686\u201394.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1068_CR75","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1111\/jdv.19427","volume":"37","author":"L Misery","year":"2023","unstructured":"Misery L, Schut C, Balieva F, et al. White paper on psychodermatology in Europe: a position paper from the EADV Psychodermatology Task Force and the European Society for Dermatology and Psychiatry (ESDaP). J Eur Acad Dermatol Venereol. 2023;37(12):2419\u201327.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1068_CR76","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijwd.2018.05.002","volume":"4","author":"L Seale","year":"2018","unstructured":"Seale L, Gaulding JV, Porto D, et al. Implementation of a psychodermatology clinic at a major health system in Detroit. Int J Womens Dermatol. 2018;4(4):227\u20139.","journal-title":"Int J Womens Dermatol."},{"issue":"2","key":"1068_CR77","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000049645","volume":"2","author":"M Silvan","year":"2001","unstructured":"Silvan M. An integrated approach to the treatment of psychodermatology patients. Dermatol Psychosom. 2001;2(2):86\u201392.","journal-title":"Dermatol Psychosom"},{"issue":"1","key":"1068_CR78","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/0019-5154.105310","volume":"58","author":"SD Shenoi","year":"2013","unstructured":"Shenoi SD, Prabhu S, Nirmal B, et al. Our experience in a psychodermatology liaison clinic at manipal, India. Indian J Dermatol. 2013;58(1):53\u20135.","journal-title":"Indian J Dermatol"},{"issue":"2","key":"1068_CR79","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2165\/11630950-000000000-00000","volume":"13","author":"E Orion","year":"2012","unstructured":"Orion E, Feldman B, Ronni W, et al. A psychodermatology clinic: the concept, the format, and our observations from Israel. Am J Clin Dermatol. 2012;13(2):97\u2013101.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1068_CR80","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0190-9622(83)70109-X","volume":"9","author":"WM Gould","year":"1983","unstructured":"Gould WM, Gragg TM. A dermatology-psychiatry liaison clinic. J Am Acad Dermatol. 1983;9(1):73\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"1068_CR81","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.6485","volume":"103","author":"S Van Beugen","year":"2023","unstructured":"Van Beugen S, Schut C, Kupfer J, et al. Perceived stigmatization among dermatological outpatients compared with controls: an observational multicentre study in 17 European countries. Acta Derm Venereol. 2023;103: adv6485.","journal-title":"Acta Derm Venereol."},{"issue":"10361","key":"1068_CR82","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0140-6736(22)01470-2","volume":"400","author":"G Thornicroft","year":"2022","unstructured":"Thornicroft G, Sunkel C, Alikhon Aliev A, et al. The Lancet Commission on ending stigma and discrimination in mental health. Lancet. 2022;400(10361):1438\u201380.","journal-title":"Lancet"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01068-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01068-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01068-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T15:09:54Z","timestamp":1710083394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01068-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01068-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"7 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive support from any organization for the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was not required for this narrative review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This review article synthesizes and analyzes information from publicly available, previously published data. All data referenced in this review are derived from existing literature, which is appropriately cited. No new data were generated or collected specifically for this review.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, literature search, and data analysis were performed by Rachel Christensen. The first draft of the manuscript was written by Rachel Christensen. All authors participated in critical revision of the manuscript. All authors read and approved of the final manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}